KPTI
vs
S&P 500
KPTI
S&P 500
Over the past 12 months, KPTI has underperformed S&P 500, delivering a return of +17% compared to the S&P 500's +18% growth.
Stocks Performance
KPTI vs S&P 500
Performance Gap
KPTI vs S&P 500
Performance By Year
KPTI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Karyopharm Therapeutics Inc
Glance View
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton Center, Massachusetts and currently employs 442 full-time employees. The company went IPO on 2013-11-06. The firm is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe and the United Kingdom, in combination with dexamethasone to treat adult patients with multiple myeloma.
